Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreFER: Insulin Detemir + Aspart vs Biphasic Aspart 30 in T2DM
NCT00605020Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2003
- Primary completion
- Mar 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of insulin detemir in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin A1c at 6 months. Started Dec 2003; status: completed.
02
Drugs
insulin detemir
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00605020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605020.